Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Epigenetic silencing including histone modifications and DNA methylation is an important tumorigenic mechanism. However, its role in cancer immunopathology and immunotherapy is poorly understood. Using human ovarian cancers as our model, here we show that enhancer of zeste homologue 2 (EZH2)-mediated histone H3 lysine 27 trimethylation (H3K27me3) and DNA methyltransferase 1 (DNMT1)-mediated DNA methylation repress the tumour production of T helper 1 (TH1)-type chemokines CXCL9 and CXCL10, and subsequently determine effector T-cell trafficking to the tumour microenvironment. Treatment with epigenetic modulators removes the repression and increases effector T-cell tumour infiltration, slows down tumour progression, and improves the therapeutic efficacy of programmed death-ligand 1 (PD-L1; also known as B7-H1) checkpoint blockade and adoptive T-cell transfusion in tumour-bearing mice. Moreover, tumour EZH2 and DNMT1 are negatively associated with tumour-infiltrating CD8(+) T cells and patient outcome. Thus, epigenetic silencing of TH1-type chemokines is a novel immune-evasion mechanism of tumours. Selective epigenetic reprogramming alters the T-cell landscape in cancer and may enhance the clinical efficacy of cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“epigenetic reprogramming with shRNAs targeting DNA methyltransferase 1 (DNMT1) or pan-DNMT blockers like decitabine and guadecitabine has been shown to resemble EZH2 inhibition in its capacity to promote CXCL9 and CXCL10 secretion in various models of breast, lung, and ovarian carcinoma”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Peng et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies have demonstrated that mutations in genes involved in the SWI-SNF chromatin remodeling complex may sensitize human tumors to ICIs and that treatment with an epigenetic modulator can potentiate the ICI-mediated antitumor response through increased production of chemokines responsible for recruiting CD8 + T cells (104-107).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [107]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The mTOR pathway has long been recognized to play a pivotal role in integrating signals at the cellular level and promote autoimmunity and carcinogenesis18,19.”
From Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation (2019) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“and TH1 cytokines”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Peng et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Self-citationIntratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
Heagerty, P. J., Lumley, T., & Pepe, M. S. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00337.x · Cited by 2,854
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Cited by
Items 701–800 of 1,000
Liu, D., Xiao, H., Xiang, Y., Zhong, D., Liu, Y., Wang, Y., & Zhang, W. (2025) · Journal of Cancer · doi:10.7150/jca.108163 · Cited by 18
Peritoneal resident macrophages in tumor metastasis and immunotherapy
Zhang, Y., Ouyang, D., Chen, Y. H., & Xia, H. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.948952 · Cited by 21
“Meanwhile, the presence of tumor infiltrating CD8 T lymphocytes is highly associated with longer survival in ovarian cancer (Zhang et al., 2003; Peng et al., 2015).”
BackgroundFeng, Y., Yan, S., Lam, S. K., Ko, F. C. F., Chen, C., Khan, M., & Ho, J. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.10.002 · Cited by 16
LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy
Luo, L., Fu, S., Du, W. T., He, L.-N., Zhang, X., Wang, Y., Zhou, Y., & Hong, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.959868 · Cited by 19
Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors
Wala, J. A., & Hanna, G. J. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.05.009 · Cited by 18
Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy
Xu, N., Tse, B., Yang, L., Tang, T. C. Y., Haber, M., Micklethwaite, K. P., & Dolnikov, A. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s296161 · Cited by 17
The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma
Wu, S.-Y., Xie, Z., Yan, L.-Y., Liu, X., Zhang, Y., Wang, D., Dong, J., & Sun, H. (2022) · BMC Immunology · doi:10.1186/s12865-022-00502-7 · Cited by 21
Schröder, M., Loos, S., Naumann, S. K., Bachran, C., Krötschel, M., Umansky, V., Helming, L., & Swee, L. K. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1258503 · Cited by 18
Vougiouklakis, T., Bao, R., Nakamura, Y., & Saloura, V. (2017) · Oncotarget · doi:10.18632/oncotarget.22627 · Cited by 18
“Other than the work performed by the Zou group [10, 11] showing that EZH2 produced by colon cancer cells mediates transcriptional silencing of Th1-type CXCL9 and CXCL10 chemokines, and causes subsequent CD8+ T-cell exclusion, no other studies have systematically explored the potential function of PMTs and PDMTs as one…”
BackgroundEngineering T cells for adoptive therapy: outsmarting the tumor
Kunert, A., & Debets, R. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.014 · Cited by 20
“Shut-down of T cell-specific chemoattractants may be linked to epigenetic silencing [16] or disruptive post-translational modifications [17,18].”
BackgroundUnderstanding genetic determinants of resistance to immune checkpoint blockers
Aspeslagh, S., Chabanon, R. M., Champiat, S., & Postel-Vinay, S. C. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.020 · Cited by 17
Lu, Y., Ma, S., Chan, Y.-T., Wu, Y., Feng, Y., & Wang, N. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.057 · Cited by 16
“Tumours often silence chemokine genes (e.g., CCL5, CXCL9/10) via DNA methylation or polycomb-mediated histone modifications (e.g., EZH2) to prevent T cell infiltration [24,25].”
House, I. G., Derrick, E. B., Sek, K., Chen, A. X. Y., Li, J., Lai, J., Todd, K. L., Munoz, I., Michie, J., Chan, C. W., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113014 · Cited by 17
Epigenome-Driven Strategies for Personalized Cancer Immunotherapy
Rocha, G. I. Y., Gomes, J. E. M., Leite, M. L., da Cunha, N. B., & Costa, F. F. (2023) · Cancer Management and Research · doi:10.2147/cmar.s272031 · Cited by 16
“6 Another example of an epigenetic mediator active in the immunotherapy of ovarian cancer is the leukemia inhibitory factor (LIF).”
BackgroundInfluentialHossain, S. M., Carpenter, C., & Eccles, M. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137252 · Cited by 16
Wang, D., Wang, W., Song, M., Xie, Y., Kuang, W., & Yang, P. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116774 · Cited by 17
Self-citationRedistribution of EZH2 promotes malignant phenotypes by rewiring developmental programmes
Mortimer, T., Wainwright, E. N., Patel, H., Siow, B. M., Jaunmuktane, Z., Brandner, S., & Scaffidi, P. (2019) · EMBO Reports · doi:10.15252/embr.201948155 · Cited by 15
Histone Modifying Enzymes in Gynaecological Cancers
Ramarao-Milne, P., Kondrashova, O., Barry, S. C., Hooper, J. D., Lee, J. S., & Waddell, N. (2021) · Cancers · doi:10.3390/cancers13040816 · Cited by 15
“EZH2 GSK126 5-AZA dC Ovarian NSG model 30 mg/kg, 3 times a week for 2 weeks Increased efficacy of adoptive T-cell therapy in vivo [58]”
BackgroundMethodUpregulated Expression of CYBRD1 Predicts Poor Prognosis of Patients with Ovarian Cancer
Chen, R., Cao, J., Jiang, W., Wang, S., & Cheng, J. (2021) · Journal of Oncology · doi:10.1155/2021/7548406 · Cited by 17
“Hindawi Journal of Oncology Volume 2021, Article ID 7548406, 14 pages https://doi.org/10.1155/2021/7548406 Moreover, TILs may contribute to tumor progression [8], the therapeutic efficacy of PD-L1 [9], and the prognostic implications of neoadjuvant chemotherapy [10].”
BackgroundInfluentialTazemetostat: a treatment option for relapsed/refractory follicular lymphoma
Mondello, P., & Ansell, S. M. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.2014815 · Cited by 16
“Preclinical models confirmed this assumption and demonstrated a synergist effect between EZH2i and PD-L1 checkpoint blockade [52].”
BackgroundGarner, I., & Brown, R. (2022) · Cancers · doi:10.3390/cancers14061533 · Cited by 17
“In pre-clinical models, the inhibition of DNMT1 and EZH2 improves the efficacy of immune checkpoint inhibitor therapy, slows tumour progression and increases TH1-cytokine production [85].”
BackgroundlncRNAs-EZH2 interaction as promising therapeutic target in cutaneous melanoma
Woźniak, M., & Czyż, M. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1170026 · Cited by 16
“, 2015) and inhibit cytokine production from T helper type 1 (Th1) CD4 T cells (Peng et al., 2015).”
BackgroundHeudobler, D., Schulz, C. K. J., Fischer, J. R., Staib, P., Wehler, T., Südhoff, T., Schichtl, T., Wilke, J., Hahn, J., Lüke, F., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.599598 · Cited by 16
“The clinical discrepancy between poor PFS in the biomodulation arm and a corresponding median OS equal to nivolumab second-line therapy may be discussed on the background of pre-clinical data showing multifold biomodulatory activities of the drug components administered in the experimental schedule (Teresi et al., 200…”
BackgroundBiomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin’s Disease
Lüke, F., Harrer, D. C., Menhart, K., Wolff, D., Holler, E., Hellwig, D., Herr, W., Grube, M., Vogelhuber, M., Reichle, A., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.599561 · Cited by 15
“It has been shown that they are able to improve T-cell function and presumably up-regulate immune-checkpoints (Peng et al., 2015; Hirayama et al., 2016; Chowdhury et al., 2018; Renner et al., 2019; Batyrova et al., 2020).”
BackgroundLin, X., Tong, X., Zhang, Y., Gu, W., Huang, Q., Zhang, Y., Zhuo, F., Zhao, F., Jin, X., Li, C., et al. (2022) · Endocrinology · doi:10.1210/endocr/bqac210 · Cited by 16
Zhang, S., Hu, Y., Zhou, Z., Lv, G., Zhang, C., Guo, Y., Wang, F., Ye, Y., Qi, H., Zhang, H., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci195970 · Cited by 16
“To investigate whether knocking down ZEB1 synergizes with chemoimmunotherapy through TIME, we orthotopically inoculated control (KPC-shV) and ZEB1 -KD KPC (KPC-sh ZEB1 ) cells into immunocompetent and immunodeficient mice under treatment with gemcitabine.”
InfluentialEZH1/2 Inhibitors Favor ILC3 Development from Human HSPC-CD34+ Cells
Damele, L., Amaro, A., Serio, A., Luchetti, S., Pfeffer, U., Mingari, M., & Vitale, C. (2021) · Cancers · doi:10.3390/cancers13020319 · Cited by 10
“The development of novel and promising therapeutic approaches in solid tumors, such as epigenetic DNA targeting, has prompted scientists to extensively evaluate the effects of these approaches on the restoring/impairing of T cell-mediated anti-tumor responses [15,16,71,72], while there are still limited data on their…”
BackgroundMultiomics characteristics and immunotherapeutic potential of EZH2 in pan-cancer
Luo, L., Wang, Z., Hu, T., Feng, Z., Zeng, Q., Shu, X., Wu, A., Huang, P., Cao, Y., Tu, Y., et al. (2023) · Bioscience Reports · doi:10.1042/bsr20222230 · Cited by 16
Epigenetic modulation and prostate cancer: Paving the way for NK cell anti-tumor immunity
dos Reis, F. D., Jerónimo, C., & Correia, M. P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1152572 · Cited by 17
“Namely, epigenetic reprogramming of chemokine expression has been reported upon treatment with DNMTi, EZH2i and LSD1, increasing tumor production of CXCL9 and CXCL10 chemokines (103, 104), known to be involved in T cell recruitment to the tumor.”
BackgroundTumor-intrinsic RGS1 potentiates checkpoint blockade response via ATF3-IFNGR1 axis
Wang, B., Jiang, B., Du, L., Chen, W., Zhang, Q., Chen, W., Ding, M., Cao, W., Gao, J., Deng, Y., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2279800 · Cited by 15
Targeting DNA Methylation Machinery in Pediatric Solid Tumors
Cristalli, C., & Scotlandi, K. (2024) · Cells · doi:10.3390/cells13141209 · Cited by 16
“As a result, interferon-gamma (IFN γ ) signaling is impaired, leading to the reduced expression of major histocompatibility complex class I molecules (MHC-Is) and type 1 T-helper (T H 1) chemokines CXCL9/CXCL10 [270,271].”
BackgroundSmyd3-mediated immuno-modulation in HPV-negative head and neck squamous cell carcinoma mouse models
Tsai, D. E., Lovanov, A., Abdelmaksoud, A. A., Akhtar, J., Dar, M. S., Luff, M. K., McKinnon, K. M., Kim, S., Robbins, Y. L., Huynh, A. P., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110854 · Cited by 14
Bowen, C. M., Düzağaç, F., Martel-Martel, A., Reyes-Uribe, L., Zaheer, M., Thompson, J. V., Deng, N., Sinha, R., Mazumdar, S., Taggart, M. W., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.177545 · Cited by 15
“While this has been observed in melanoma, other studies found that CRC cells exhibit similar repression of CD8 + cytotoxic T cell trafficking to tumor sites, suggesting that the epigenetic silencing of immune pathways is a vital mechanism in CRC biology (10, 31).”
Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer
Cho, J. H., Öezkan, F., Koenig, M. J., Otterson, G. A., Herman, J. G., & He, K. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-017-0110-5 · Cited by 14
CD8+ T Cells in Immunotherapy, Radiotherapy, and Chemotherapy
Wang, W., Green, M. D., Liu, J. R., Lawrence, T. S., & Zou, W. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_3 · Cited by 21
Self-citationUBE3A deletion enhances the efficiency of immunotherapy in non-small-cell lung cancer
Zhang, N., Shen, J., Gou, L.-Y., Cao, M., Ding, W., Luo, P., & Zhang, J. (2022) · Bioengineered · doi:10.1080/21655979.2022.2069328 · Cited by 16
“Previous studies have revealed that the Th1 chemokines CXCL9 and CXCL10 enhance the tumor attack of effector T cells and increase PD-L1 blockade [47].”
ResultWu, Y., Yu, S., & Qiao, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.990445 · Cited by 16
“In addition, CCR5-CCL4/5 has also been found to be associated with the infiltration of TILs through multiple pathways.”
BackgroundInfluentialEpigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma
Li, Y., Hong, Y. K., Wang, X., Pandit, H., Zheng, Q., Yu, Y., Shi, X., Chen, Y., Tan, M., Pulliam, Z., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1430 · Cited by 14
“Chemokines CXCL9 and CXCL10 are known to be aberrantly methylated and play a critical role in immune trafficking across tumour microenvironments.(23,34) Given the epigenetically repressed CXCL9 and CXCL10 as a known barrier for immunotherapy, we demonstrated an upregulation of chemokines CXCL9 and CXCL10 in two human…”
BackgroundCalanca, N., Francisco, A. L. N., Bizinelli, D., Kuasne, H., Barros‐Filho, M. C., Flores, B. C. T., Pinto, C. A. L., Rainho, C. A., Soares, M. B. P., Marchi, F. A., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115559 · Cited by 14
Pharmacological Polarization of Tumor‐Associated Macrophages Toward a CXCL9 Antitumor Phenotype
Enbergs, N., Halabi, E. A., Goubet, A., Schleyer, K. A., Fredrich, I. R., Köhler, R. H., Garris, C., Pittet, M. J., & Weissleder, R. (2024) · Advanced Science · doi:10.1002/advs.202309026 · Cited by 17
Mondino, A., Vella, G., & Icardi, L. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.006 · Cited by 16
Towards In Silico Prediction of the Immune-Checkpoint Blockade Response
Chen, K., Ye, H., Lu, X., Sun, B., & Liu, Q. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.10.002 · Cited by 14
Wang, B., Mou, H., Liu, M., Ran, Z., Li, X., Li, J., & Ou, Y. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00202-y · Cited by 16
A Tumor Cell-Intrinsic Yin-Yang Determining Immune Evasion
Horton, B. L., & Spranger, S. (2018) · Immunity · doi:10.1016/j.immuni.2018.07.001 · Cited by 15
“Indeed, alterations in signaling pathways have been reported to be associated with the non-T-cell-inflamed TME in melanoma, lung cancer, and ovarian cancer (Peng et al., 2015; Spranger et al., 2015; Spranger et al., 2017).”
BackgroundShi, Y., Liu, Z., & Wang, H.-T. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17390 · Cited by 13
Sumimoto, H., Takano, A., Igarashi, T., Hanaoka, J., Teramoto, K., & Daigo, Y. (2023) · Scientific Reports · doi:10.1038/s41598-023-32177-4 · Cited by 15
Roy, A. M., & George, S. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.47 · Cited by 14
Targeting epigenetic mechanisms of resistance to chemotherapy in gliomas
Skouras, P., Markouli, M., Papadatou, I., & Piperi, C. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104532 · Cited by 14
Polycomb repressive complex 2 (PRC2) pathway’s role in cancer cell plasticity and drug resistance
Goleij, P., Heidari, M. M., Tabari, M. A. K., Hadipour, M., Rezaee, A., Javan, A., Sanaye, P. M., Larsen, D. S., Daglia, M., & Khan, H. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01563-8 · Cited by 17
“A CD8 + T cell trafficking repression effect of PRC2 been observed in ovarian and colon cancer (Nagarsheth et al. 2016; Peng et al. 2015).”
InfluentialAquino, A., & Franzese, O. (2025) · Cancers · doi:10.3390/cancers17091547 · Cited by 13
Immune Checkpoint Molecules in Hodgkin Lymphoma and Other Hematological Malignancies
Alibrahim, M. N., Carbone, A., Alsaleh, N., & Gloghini, A. (2025) · Cancers · doi:10.3390/cancers17142292 · Cited by 14
“The silencing of MHC class I transactivators or CXCL9/10 impairs antigen presentation and T-cell recruitment, respectively [203–205].”
Zhang, Z., Zhu, Y., Xu, D., Li, T., Li, J., Xiao, Z.-T., Chen, M., Yang, X. L., Jia, H., Dong, Q., et al. (2021) · American Journal of Translational Research · Cited by 18
Tailoring therapies to counter the divergent immune landscapes of breast cancer
Attalla, S. S., Taifour, T., & Muller, W. J. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1111796 · Cited by 16
“Work using ovarian cancer models demonstrated that inhibition of EZH2 induced expression of inflammatory cytokines C-X-C ligand (CXCL) 9 and CXCL10 that promoted recruitment of cytotoxic T-cells into the tumor (Peng et al., 2015).”
BackgroundRubatto, M., Borriello, S., Sciamarrelli, N., Pala, V., Tonella, L., Ribero, S., & Quaglino, P. (2023) · Melanoma Research · doi:10.1097/cmr.0000000000000926 · Cited by 14
“The realm of epigenetic alterations occupies a pivotal role in the context of cancer prognosis and augmentation of immunotherapeutic effects [129,130].”
BackgroundNext-generation immunotherapies for lymphoma: one foot in the future
Manson, G., & Houot, R. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy032 · Cited by 17
Switching on the green light for chimeric antigen receptor T‐cell therapy
Mardiana, S., Lai, J., House, I. G., Beavis, P. A., & Darcy, P. K. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1046 · Cited by 15
“However, a recent study utilising a xenograft model of ovarian cancer demonstrated that co-administration of T cells with the EZH2 inhibitor, GSK126, and DNA methyltransferase inhibitor, 5-AZA-dC, led to a significant enhancement in CXCR3-dependent trafficking and antitumor efficacy.(52) This regime was shown to augme…”
BackgroundImmune landscape and therapeutic strategies: new insights into PD-L1 in tumors
Yuan, W., Xiao, C., Lao, X., Zheng, L., & Kuang, D. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03637-1 · Cited by 14
“In fact, further investigation utilizing humanized mouse models has confirmed that abrogating EZH2-mediated histone modifications and DNA methyltransferase 1 (DNMT)-mediated DNA methylation does improve the therapeutic efficacy of PD-L1 blockade in ovarian cancer [129].”
BackgroundZhu, J., Li, L., TONG, J. H. M., Hui, C. W. C., Wong, C. H., Lo, K. W., Chan, R. N. C., Ai, Q. Y. H., Hui, E. P., Chan, A. T. �., et al. (2020) · PubMed · Cited by 15
Xu, J.-L. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07620-7 · Cited by 13
“A previous study showed that CXCL10 in cancers promoted T-cell recruitment and enforced T-cell immunotherapy [45].”
MethodLuo, Y., Lu, J., Lei, Z., Zhu, H., Rao, D., Wang, T., Fu, C., Zhang, Z., Xia, L., & Huang, W. (2024) · Biomarker Research · doi:10.1186/s40364-024-00621-w · Cited by 13
“Additionally, tumor EZH2 levels exhibited a negative correlation with tumor-infiltrating CD8 + T cells and were associated with a poorer patient prognosis [147].”
BackgroundThe Therapeutic Potential of Physical Exercise in Cancer: The Role of Chemokines
Buzaglo, G. B. B., Telles, G. D., Araújo, R. B., Dias, G., Ruberti, O. M., Ferreira, M. L. V., Derchain, S., VECHIN, F. C., & Conceição, M. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413740 · Cited by 15
“The CXCR3-CXCL9/CXCL10 chemokine axis, mobilized by Th1 cells [74,75], can also participate in antitumor responses remodeling tumor immunity through the production of interferon gamma (IFN-γ ).”
Ramos-Ramírez, M., Caballé‐Perez, E., Lucio-Lozada, J., Romero-Núñez, E., Castillo-Ruiz, C., Dorantes-Sánchez, L., Flores‐Estrada, D., Recondo, G., Barrios‐Bernal, P., Cabrera-Miranda, L. A., et al. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10245-7 · Cited by 15
“In addition, PI3K-AKT-mTOR drives immunosuppressive remodeling of the TME by upregulating CXCL10 and CCL2 [60, 61], which increases the infiltration of Tregs and M2 macrophages [62], and decreases the presence of CD45-positive leukocytes, NK cells, dendritic cells, M1 macrophages, T CD8 +…”
Timpanaro, A., Song, E. Z., Emwas, N., Chiu, C.-H., Ronsley, R. J., Taylor, M. R., Foster, J., Wang, L. D., & Vitanza, N. A. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1465 · Cited by 13
Inhibition of MBTPS1 enhances antitumor immunity and potentiates anti-PD-1 immunotherapy
Wang, Y.-Y., Lin, J., Wu, W.-W., Fu, Z., Cao, F., Chen, Y., Mo, H., Hui, S., Liu, Z., Zeng, Z.-L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59193-4 · Cited by 14
Rethinking ovarian cancer III: the past decade and future directions
Balkwill, F. R., Laumont, C. M., Burdett, N. L., Saux, O. L., Garsed, D. W., Grither, W. R., Nijhuis, A. M., Recouvreux, M. S., Kang, Z., Zhang, R., et al. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00916-0 · Cited by 20
“In ‘inflamed’ tumours, that is, tumours with a strong inflammatory infiltrate, antigen-specific T cells secrete interferon-γ (IFNγ), which activates myeloid antigen-presenting cells to recruit additional CD8 + TIL-Ts via CXCL9 155,156 together with tumour-derived CC-chemokine ligand 5 (CCL5).”
Xu, X., Guo, W., Pan, S., Zhang, Y., Gao, F., Wang, J.-T., Zhang, S., Li, H.-Y., Wang, R., & Zhang, X. (2020) · Aging · doi:10.18632/aging.103798 · Cited by 13
“Moreover, EZH2 and DNMT1 are negatively associated with tumor-infiltrating CD8+ T cells [20].”
BackgroundPayload Delivery: Engineering Immune Cells to Disrupt the Tumour Microenvironment
Fowler, D. W., Nattress, C. B., Southern, A., Barisa, M., & Fisher, J. P. H. (2021) · Cancers · doi:10.3390/cancers13236000 · Cited by 13
“Added to this, there is the further complexity of tumours using epigenetic silencing to switch off production of Th1‐based chemokines such as CXCL9 and CXCL10, a novel immune escape mechanism employed by tumours to reduce infiltration by cytotoxic effector cells [35].”
BackgroundAdoptive cell therapies in thoracic malignancies
Lasvergnas, J., Naigeon, M., Chouahnia, K., Zelek, L. H., Chaput, N., & Duchemann, B. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03142-3 · Cited by 12
“Combinations with other immune therapies could also be a solution, since the TME might have a role in inactivating infused NK cells [45].”
BackgroundInfluentialTargeting Epigenetic Mechanisms: A Boon for Cancer Immunotherapy
Parab, A., Bhatt, L. K., & Omri, A. (2023) · Biomedicines · doi:10.3390/biomedicines11010169 · Cited by 13
T cell‐dependent bispecific antibodies alter organ‐specific endothelial cell–T cell interaction
Himmels, P., Nguyen, T. T. T., Caunt, M., Arrazate, A., Yeung, S., Burton, J., Clark, R., Tótpál, K., Jesudason, R., Yang, Y. A., et al. (2023) · EMBO Reports · doi:10.15252/embr.202255532 · Cited by 13
“…in solid tumors is an important requirement for antitumor activity of T cells and has been shown to correlate with responses to cancer immunotherapies (Pockaj et al , 1994; Ji et al , 2012; Peng et al , 2015; Spranger et al , 2015; Chen et al , 2016; Wang et al , 2016; Li et al , 2019).”
Exploring the therapeutic potential of targeting polycomb repressive complex 2 in lung cancer
Gao, M., Li, Y., Cao, P., Liu, H., Chen, J., & Kang, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1216289 · Cited by 14
“In ovarian tumors, EZH2 expression was negatively correlated with intratumoral CD8+ T cells, and its expression inhibited the production of CXCL9 and CXCL10, thereby affecting CD8+ T cell in fi ltration within the tumor (37, 38).”
BackgroundJohnson, N., & Liao, J. B. (2017) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000001115 · Cited by 12
“Epigenetic reprogramming through DNA methylation has also been shown to alter T-cell trafficking to tumors.(9,10) Alternate approaches to prevent immune escape of tumor may rest with strategies such as the selective depletion of macrophages and targeting theunique features of the tumormicroenvironment.”
BackgroundOvercoming immune suppression with epigenetic modification in ovarian cancer
McCaw, T. R., Randall, T. D., & Arend, R. C. (2018) · Translational research · doi:10.1016/j.trsl.2018.06.003 · Cited by 14
Histone Modifications as Biomarkers for Immunotherapy
Taylor, E. M., Koss, B. S., Davis, L. E., & Tackett, A. J. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_10 · Cited by 13
Miyashita, N., Horie, M., Mikami, Y., Urushiyama, H., Fukuda, K., Miyakawa, K., Matsuzaki, H., Makita, K., Morishita, Y., Harada, H., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.06.002 · Cited by 14
Boila, L. D., & Sengupta, A. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.09.189 · Cited by 13
“Dissecting the role of T cell exhaustion in cancer progression: a multifaceted approach“
Li, X., & Song, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1646292 · Cited by 13
Lofiego, M. F., Cannito, S., Fazio, C., Piazzini, F., Cutaia, O., Solmonese, L., Marzani, F., Chiarucci, C., Giacomo, A. M. D., Calabrò, L., et al. (2021) · Epigenomes · doi:10.3390/epigenomes5040027 · Cited by 19
“Since epigenetic modifications are known to contribute to the highly MPM immunosuppressive microenvironment [19], it is reasonable to explore the efficacy of epigenetic compounds in MPM, in the attempt to improve tumor immunogenicity, remodel tumor phenotype and provide a rationale for epigenetic-based strategies able…”
BackgroundCancer Vaccine in Cold Tumors: Clinical Landscape, Challenges, and Opportunities
Rezaei, M., Danilova, N. D., Soltani, M., Savvateeva, L. V., Tarasov, V. V., Ganjalıkhani-Hakemi, M., Bazhin, A. V., & Zamyatnin, A. A. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220214103533 · Cited by 12
Drug Repurposing by Tumor Tissue Editing
Lüke, F., Harrer, D. C., Pantziarka, P., Pukrop, T., Ghibelli, L., Gerner, C., Reichle, A., & Heudobler, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.900985 · Cited by 11
“The combination with ICIs is at least promising in pre-clinical trials., as immunosurveillance may be reestablished by increase of tumor infiltrating T-cells and a parallel decrease of regulatory T-cells (142, 143).”
BackgroundInfluentialQiang, N., Ao, J., Nakamura, M., Chiba, T., Kusakabe, Y., Kaneko, T., Kurosugi, A., Kogure, T., Ma, Y., Zhang, J., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110068 · Cited by 11
Survivin prevents the polycomb repressor complex 2 from methylating histone 3 lysine 27
Jensen, M., Chandrasekaran, V., García-Bonete, M.-J., Li, S., Anindya, A. L., Andersson, K., Erlandsson, M. C., Oparina, N. Y., Burmann, B. M., Brath, U., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106976 · Cited by 11
Zakharia, Y., Singer, E. A., Acharyya, S., Garje, R., Joshi, M., Peace, D. J., Baladandayuthapani, V., Majumdar, A., Xiong, L., Lalancette, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45216-z · Cited by 11
“Preclinical data suggest hypermethylation-induced silencing of TH1-type chemokines signaling results in tumor immune evasion in RCC cell lines (A-498, HTB-46, and CRL-1611) 7 .”
BackgroundSelf-citationBaba, R. E., & Herbein, G. (2024) · Cells · doi:10.3390/cells13060541 · Cited by 11
“This upregulation Thus, combining EZH2 inhibition with immunotherapy improves T-cell infiltration, promoting IFN-γ -producing CD8+ T cells in the TME and enhancing tumor control [82,85].”
BackgroundMethodRethinking Immune Check Point Inhibitors Use in Liver Transplantation: Implications and Resistance
Ortiz, V., & Loeuillard, E. J. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.101407 · Cited by 13
Epigenetics, a key player of immunotherapy resistance
Peixoto, P., Renaude, E., Boyer‐Guittaut, M., & Hervouet, É. (2018) · Cancer Drug Resistance · doi:10.20517/cdr.2018.17 · Cited by 10
“For example, the HMT enhancer of zeste homolog 2, which mediates the trimethylation of histone H3 lysine 27 (H3K27me3), and DNMT1 which repressed the production and secretion of CXCL9 and CXCL10 by Th1 therefore inhibited the recruitment of CD8 T-cells within the tumor in ovarian cancer models([1]).”
BackgroundMechanisms of Resistance to PD-1 Checkpoint Blockade
Moser, J. C., & Hu‐Lieskovan, S. (2020) · Drugs · doi:10.1007/s40265-020-01270-7 · Cited by 11
Park, C., Jeong, K., Park, J.-H., Jung, S., Bae, J. M., Kim, K., Ock, C., Kim, M., Keam, B., Kim, T. M., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02796-1 · Cited by 27
Immunogenomic landscape of gynecologic carcinosarcoma
Gotoh, O., Kiyotani, K., Chiba, T., Sugiyama, Y., Takazawa, Y., Nemoto, K., Kato, K., Tanaka, N., Nomura, H., Hasegawa, K., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.11.030 · Cited by 11
Liu, Y., & Wang, X. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02602-z · Cited by 12
Novel classes of immunotherapy for breast cancer
Hernando‐Calvo, A., Cescon, D. W., & Bedard, P. L. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06405-2 · Cited by 12
Zeng, H., Tong, F., Bin, Y., Peng, L., Gao, X., Xia, X., Yi, X., & Dong, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.834142 · Cited by 11
“CXCL9, a ligand of CXCR3, which plays an essential role in the activation and recruitment of CD8+T cells (72), is not only correlated with the improved response of chemotherapy (73) and adoptive cellular therapy (74) but also with the antitumor immune responses following ICI immunotherapy (75), thereby suggesting the…”
BackgroundYan, Y., Upadhyaya, R., Zhang, V. W., & Berg, T. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.03.003 · Cited by 11
Nuclear Coregulatory Complexes in Tregs as Targets to Promote Anticancer Immune Responses
Christensen, L. M., & Hancock, W. W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.909816 · Cited by 12
“Cancer cells that express EZH2 have reduced CXCR9 expression (105) and decreased effector T-cell infiltration of tumors (106).”
BackgroundWang, S., Fu, J., & Fang, X. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01142-0 · Cited by 11
Miyahira, A. K., Roychowdhury, S., Goswami, S., Ippolito, J. E., Priceman, S. J., Pritchard, C. C., Sfanos, K. S., Subudhi, S. K., Simons, J. W., Pienta, K. J., et al. (2016) · The Prostate · doi:10.1002/pros.23260 · Cited by 11
“For example, recent studies have demonstrated that epigenetic modulation of effector T cell function via the methyltransferase EZH2 controls anti-tumor immunity, and targeting this pathway has potential therapeutic applications with other immunotherapies [68,69].”
BackgroundPotts, M. A., McDonald, J. A., Sutherland, K. D., & Herold, M. J. (2020) · European Journal of Immunology · doi:10.1002/eji.202048712 · Cited by 12
Giehl, E., Kosaka, H., Liu, Z., Feist, M., Kammula, U. S., Lotze, M. T., Ma, C., Guo, Z. S., & Bartlett, D. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.610042 · Cited by 11
Jin, M. C., Connolly, I. D., Ravi, K., Tobert, D. G., MacDonald, S. M., & Shin, J. H. (2024) · Neurosurgical FOCUS · doi:10.3171/2024.2.focus2417 · Cited by 11
Wang, Z., Xie, M., Jia, Z., Tao, Z., Zhao, P., & Ying, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-72578-7 · Cited by 10
“At the same time, fatty acid can inhibit the anti-tumor activity of T cells 32 and promote the expression of T cells immune checkpoints, thus making T cells more likely to be inhibited 33 .”
Metadata
- Authors
- Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., Kotarski, J., Tarkowski, R., Dou, Y., Cho, K., Hensley-Alford, S., Munkarah, A., Liu, R., & Zou, W.
- Affiliations
- University of Michigan (US)
- Medical University of Lublin (PL)
- Henry Ford Health (US)
- Corresponding author
- Zou, Weiping
- ORCID
- Venue
- Nature
- Published
- 2015-10-26
- Volume
- 527
- Issue
- 7577
- Pages
- 249-253
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4779053
- OpenAlex
- W2103021272
- Cited by
- 1,201
- References
- 37
- Citations by year
- 2026: 79 · 2025: 100 · 2024: 104 · 2023: 132 · 2022: 155 · 2021: 159 · 2020: 125 · 2019: 109 · 2018: 85 · 2017: 89 · 2016: 61 · 2015: 2
- FWCI
- 34.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (CA099985, R01CA123088, R01CA152470, CA193136, R01CA156685, CA123088, 5P30 CA 46592, CA156685, CA152470, R01CA171306, R01CA193136, CA171306, R01CA099985, F31CA189440, R01CA190176, CA190176, P30CA046592)
- National Institute of General Medical Sciences (R01GM082856)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- epigenetic silencing, EZH2, DNMT1, CXCL9, CXCL10, ovarian cancer, tumor immunosuppression, adoptive T cell therapy, CD8+ T cells, H3K27me3, DNA methylation, histone modifications, tumor microenvironment, immunotherapy response
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, DNA (Cytosine-5-)-Methyltransferase 1, Animals, DNA (Cytosine-5-)-Methyltransferases, Female, Histones, Humans, Immunotherapy, Lysine, Ovarian Neoplasms, Prognosis, Tumor Cells, Cultured, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Th1 Cells, Chemokines, Tumor Escape, DNA Methylation, Gene Silencing, Xenograft Model Antitumor Assays, Epigenesis, Genetic, Mice, Chemokine CXCL10, Chemokine CXCL9, B7-H1 Antigen, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.